A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Recruiting

Phase 1

TirabrutinibA Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Sponsor:

Ono Pharmaceutical Co. Ltd

Code:

NCT07198087

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Tirabrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-02. This information was provided to ClinicalTrials.gov by Ono Pharmaceutical Co. Ltd on 2025-10-20.